JPH10508295A - 細胞サイトゾルへの分子移入 - Google Patents
細胞サイトゾルへの分子移入Info
- Publication number
- JPH10508295A JPH10508295A JP8509404A JP50940496A JPH10508295A JP H10508295 A JPH10508295 A JP H10508295A JP 8509404 A JP8509404 A JP 8509404A JP 50940496 A JP50940496 A JP 50940496A JP H10508295 A JPH10508295 A JP H10508295A
- Authority
- JP
- Japan
- Prior art keywords
- cytosol
- compound
- molecules
- cells
- released
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Catalysts (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.光増感性化合物と該光増感性化合物に吸収される光とを用いることによっ て生細胞のサイトゾルに分子類を導入する方法において、 a)互いに結合しているかまたは分離している、前記光増感性化合物、任意の ベクター分子、および輸送すべき分子(類)を生細胞に与え; b)次いで、飲食作用によりまたは他の方法にて、前記光増感性化合物、前記 担体分子および前記分子(類)を、エンドソーム、リソソームまたは他の細胞内 の膜制限区画に移動させ、それにより、細胞を; c)所望の生存率に依存して量を変化させた、前記光増感性化合物の吸収スペ クトルに応じた適当な波長の光に曝すことにより、エンドソーム膜、リソソーム 膜または他の細胞内区画膜を破壊し、前記サイトゾルに導入されるべき分子類を 前記サイトゾルに放出し、そして光活性化された光増感性化合物は自身で細胞の 大部分を殺さないことを特徴とする分子導入方法。 2.前記サイトゾルに放出される分子類は、DNA、オリゴ(デオキシ)ヌクレ オチド、mRNA、アンチセンスDNA、糖類、タンパク質類、ペプチド類、膜不浸透 性薬物類、他の膜不浸透性分子類、および前記分子類の共有結合または非共有結 合した組合せを含む群から選択されることを特徴とする請求項1記載の方法。 3.前記サイトゾルに放出される分子類は、タンパク質合成活性を修飾する物 質の群から選択されることを特徴とする請求項1記載の方法。 4.前記サイトゾルに放出される化合物は、ゲロニン、サポリンまたはアグロ スチンまたはこれらのいずれかの組合せであることを特徴とする請求項2記載の 方法。 5.使用される光増感性化合物は、ポルフィリン類、フタロシアニン類、プル プリン類、クロリン類、ベンゾポルフィリン類、ナフタロシアニン類、カチオン 性色素類、テトラサイクリン類およびリソソーム指向性塩基類およびこれらの誘 導体を含む群から選択されることを特徴とする請求項1記載の方法。 6.使用される光増感性化合物は、隣接するフェニル基上に2個のスルホネー ト基を持つテトラフェニルポルフィン(TPPS2a)、4個のスルホネート基を持つ メソテトラフェニルポルフィン(TPPS4)または隣接するフェニル環上に2個の スルホネート基を持つアルミニウムフタロシアニン(AlPcS2a)またはこれらの いずれかの組合せであることを特徴とする請求項5記載の方法。 7.使用するベクター分子類は、光増感性化合物またはサイトゾルに放出され るべき分子類の摂取を容易とする、部位−指向性分子類またはエンハンサ類であ ることを特徴とする請求項1記載の方法。 8.細胞の生存分率は、光増感性化合物の濃度に関連した光量を 選択することによって調節されることを特徴とする請求項1記載の方法。 9.サイトゾルに放出されるべき化合物と光増感剤と担体とを含有する、温血 動物または細胞培養における新生物および他の細胞プロセスの修飾用組成物にお いて、 a)サイトゾルに放出されるべき細胞のプロセス−修飾化合物と、光活性化に 際して細胞内区画膜を破壊する光増感性化合物との双方に結合され、エンドソー ム、リソソームまたは他の細胞内区画のごとき細胞内区画への移動を容易とする 担体、 b)サイトゾルに放出されるべき化合物に結合された少なくとも1つの担体、 及び前記光増感性化合物に結合されたもう1つの同様のまたは同様ではない担体 のうちのいくつか、及び c)サイトゾルに放出されるべき化合物と前記光増感性化合物と共に分離され ている担体類の混合物、 からなる群から選択される構成部分を備えることを特徴とする。 10.前記サイトゾルに放出されるべき前記化合物は抗新生物化合物であること を特徴とする請求項9記載の組成物。 11.前記抗新生物化合物はゲロニンであることを特徴とする請求項10記載の組 成物。 12.サイトゾルに放出される前記化合物は、DNA、オリゴ(デオキシ)ヌクレ オチド、mRNA、アンチセンスDNA、糖類、タンパク質類、ペプチド類、膜不浸透 性薬物類、他の膜不浸透性分子類、および前記分子類の共有結合したまたは非共 有結合した組合せを含む群 から選択されることを特徴とする請求項9記載の組成物。 13.前記光増感性化合物は、ポルフィリン類、フタロシアニン類、プルプリン 類、クロリン類、ベンゾポルフィリン類、ナフタロシアニン類、カチオン性色素 類、テトラサイクリン類およびリソソーム指向性塩基類およびそれらの誘導体を 含む群から選択されることを特徴とする請求項9記載の組成物。 14.前記光増感性化合物は、隣接するフェニル基上に2個のスルホネート基を 持つテトラフェニルポルフィンであることを特徴とする請求項11記載の組成物。 15.前記担体は、光増感性化合物またはサイトゾルに放出されるべき分子類の 摂取を容易とする、部位−指向性分子類またはエンハンサ類から選択されること を特徴とする請求項9記載の組成物。 16.光増感性化合物類と、細胞膜輸送を修飾し、ある種の細胞集団または他の 関連機能を容易とする化合物類とを含有することを特徴とする請求項1記載の方 法を実施するためのキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO943327A NO180167C (no) | 1994-09-08 | 1994-09-08 | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
NO943327 | 1994-09-08 | ||
PCT/NO1995/000149 WO1996007432A1 (en) | 1994-09-08 | 1995-09-04 | Transfer of molecules into the cytosol of cells |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10508295A true JPH10508295A (ja) | 1998-08-18 |
JP4148328B2 JP4148328B2 (ja) | 2008-09-10 |
Family
ID=19897382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50940496A Expired - Fee Related JP4148328B2 (ja) | 1994-09-08 | 1995-09-04 | 細胞サイトゾルへの化合物の移入 |
Country Status (20)
Country | Link |
---|---|
US (3) | US5876989A (ja) |
EP (1) | EP0783323B1 (ja) |
JP (1) | JP4148328B2 (ja) |
KR (2) | KR100395615B1 (ja) |
CN (1) | CN1222309C (ja) |
AT (1) | ATE209507T1 (ja) |
AU (1) | AU700797B2 (ja) |
BR (1) | BRPI9508825B8 (ja) |
CA (1) | CA2199290C (ja) |
CZ (1) | CZ65897A3 (ja) |
DE (1) | DE69524238T2 (ja) |
ES (1) | ES2163527T3 (ja) |
FI (1) | FI121328B (ja) |
HK (1) | HK1004110A1 (ja) |
HU (1) | HU222984B1 (ja) |
MX (1) | MX9701676A (ja) |
NO (1) | NO180167C (ja) |
NZ (2) | NZ293008A (ja) |
PT (1) | PT783323E (ja) |
WO (1) | WO1996007432A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541072A (ja) * | 1999-03-15 | 2002-12-03 | フォトキュア エイエスエイ | 方 法 |
JP2004520020A (ja) * | 2000-11-29 | 2004-07-08 | ピーシーアイ バイオテック エイエス | ウィルス媒介の細胞質中への分子送達のための光化学的内在化 |
JP2004520021A (ja) * | 2000-11-29 | 2004-07-08 | ピーシーアイ バイオテック エイエス | 細胞質中への分子送達のための光化学的内在化 |
JP2005507383A (ja) * | 2001-08-30 | 2005-03-17 | ピーシーアイ バイオテック エイエス | 化合物 |
JP4593857B2 (ja) * | 1999-09-09 | 2010-12-08 | 株式会社東京大学Tlo | 膜の穿孔方法および装置 |
JP2021512063A (ja) * | 2018-01-24 | 2021-05-13 | ピーシーアイ バイオテック エイエス | 方法 |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
US6176842B1 (en) * | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
US6210356B1 (en) * | 1998-08-05 | 2001-04-03 | Ekos Corporation | Ultrasound assembly for use with a catheter |
JP4383545B2 (ja) * | 1997-03-19 | 2009-12-16 | ルーシド インコーポレーテッド | 共焦点顕微鏡使用法を利用する細胞手術 |
US6676626B1 (en) | 1998-05-01 | 2004-01-13 | Ekos Corporation | Ultrasound assembly with increased efficacy |
US6582392B1 (en) | 1998-05-01 | 2003-06-24 | Ekos Corporation | Ultrasound assembly for use with a catheter |
EP2138191A1 (en) | 1998-01-05 | 2009-12-30 | University Of Washington | Enhanced transport using membrane disruptive agents |
US6399769B1 (en) * | 1998-01-20 | 2002-06-04 | Kimberly-Clark Worldwide, Inc. | Method of making sulfanatophenyl substituted porphines |
IL154044A0 (en) * | 2000-07-21 | 2003-07-31 | Essentia Biosystems Inc | Multi-component pharmaceutical compositions containing a complex of a positively charged backbone and a negatively charged backbone and methods for the preparation thereof |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US20020098472A1 (en) * | 2000-11-30 | 2002-07-25 | Erlach Julian Van | Method for inserting a microdevice or a nanodevice into a body fluid stream |
US20020137901A1 (en) * | 2001-01-22 | 2002-09-26 | Cavanaugh Philip Gerard | Synthesis, and photodynamic therapy-mediated anti-cancer, and other uses of chlorin e6-transferrin |
US20030031655A1 (en) * | 2001-02-08 | 2003-02-13 | Sequitur, Inc. | Methods of light activated release of ligands from endosomes |
DK1407787T3 (da) * | 2001-06-20 | 2009-06-02 | Dainippon Sumitomo Pharma Co | Fremgangsmåde til fremme af nukleinsyreoverförsel |
ATE319378T1 (de) | 2001-12-03 | 2006-03-15 | Ekos Corp | Katheter mit mehreren ultraschall-abstrahlenden teilen |
US7141044B2 (en) * | 2001-12-11 | 2006-11-28 | Ekos Corporation | Alternate site gene therapy |
WO2003064625A2 (en) | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Oligonucleotide compositions with enhanced efficiency |
US20060009409A1 (en) * | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
US8226629B1 (en) | 2002-04-01 | 2012-07-24 | Ekos Corporation | Ultrasonic catheter power control |
US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
GB0215534D0 (en) * | 2002-07-04 | 2002-08-14 | Ecole Polytech | Selective photochemotherapy using oligonucleotide targeting agents |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
US6921371B2 (en) * | 2002-10-14 | 2005-07-26 | Ekos Corporation | Ultrasound radiating members for catheter |
JP2006517790A (ja) * | 2003-01-09 | 2006-08-03 | インヴィトロジェン コーポレーション | ポリペプチド−核酸複合体の細胞の送達および活性化 |
US7332477B2 (en) * | 2003-07-10 | 2008-02-19 | Nitto Denko Corporation | Photocleavable DNA transfer agent |
EP1667732B1 (en) * | 2003-09-29 | 2010-04-21 | Nitto Denko Corporation | Biodegradable polyacetals for in vivo polynucleotide delivery |
US20080318319A1 (en) * | 2003-12-19 | 2008-12-25 | Yoshiko Minakuchi | Novel Method of Nucleic Acid Transfer |
CA3031270A1 (en) | 2004-03-03 | 2005-12-22 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
EP1729821B1 (en) * | 2004-03-03 | 2013-07-17 | ReVance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
GB0415263D0 (en) * | 2004-07-07 | 2004-08-11 | Norwegian Radium Hospital Res | Method |
US20060094781A1 (en) * | 2004-11-04 | 2006-05-04 | Syneron Medical Ltd. | Method of treating extracellular matrix |
FR2877943B1 (fr) * | 2004-11-16 | 2008-09-05 | Univ De Coimbra | Nouveaux derives de porphyrine, notamment chlorines et/ou bacteriochlorine, et leurs applications en therapie photodynamique |
RU2007136616A (ru) | 2005-03-03 | 2009-04-10 | Риванс Терапьютикс, Инк. (Us) | Композиция и способ для местного применения и чрескожного введения ботулинового токсина |
SG160358A1 (en) * | 2005-03-03 | 2010-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
US7674452B2 (en) * | 2005-03-16 | 2010-03-09 | Nitto Denko Corporation | Polymer coating of cells |
BRPI0501037B8 (pt) * | 2005-03-18 | 2021-07-27 | Fund De Amparo A Pesquisa Do Estado De Sao Paulo | uso de crotamina e composição |
US8518414B2 (en) * | 2005-11-17 | 2013-08-27 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
WO2007109584A1 (en) * | 2006-03-16 | 2007-09-27 | University Of Washington | Temperature-and ph-responsive polymer compositions |
GB0613753D0 (en) * | 2006-07-11 | 2006-08-23 | Norwegian Radium Hospital Res | Method |
EP2099496A2 (en) * | 2006-12-08 | 2009-09-16 | Massachusetts Institute of Technology | Delivery of nanoparticles and/or agents to cells |
AU2007340162B2 (en) * | 2006-12-29 | 2013-08-01 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT |
CN101583274A (zh) * | 2006-12-29 | 2009-11-18 | 雷文斯治疗公司 | 使用反向序列hiv-tat多肽的运输分子 |
US10182833B2 (en) | 2007-01-08 | 2019-01-22 | Ekos Corporation | Power parameters for ultrasonic catheter |
US7981688B2 (en) | 2007-03-08 | 2011-07-19 | University Of Washington | Stimuli-responsive magnetic nanoparticles and related methods |
PL2170181T3 (pl) | 2007-06-22 | 2014-08-29 | Ekos Corp | Sposób i aparat do leczenia wylewów wewnątrzczaszkowych |
WO2009079415A1 (en) * | 2007-12-14 | 2009-06-25 | Ekos Corporation | Ultrasound pulse shaping |
GB0811955D0 (en) | 2008-06-30 | 2008-07-30 | Pci Biotech As | Method |
US8426214B2 (en) * | 2009-06-12 | 2013-04-23 | University Of Washington | System and method for magnetically concentrating and detecting biomarkers |
GB0914287D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Compositions |
GB0914286D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Method |
US9080933B2 (en) | 2009-11-09 | 2015-07-14 | University Of Washington Through Its Center For Commercialization | Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates |
US20110117668A1 (en) * | 2009-11-09 | 2011-05-19 | University Of Washington Through Its Center For Commercialization | Self-powered smart diagnostic devices |
GB201208548D0 (en) | 2012-05-15 | 2012-06-27 | Pci Biotech As | Compound and method |
CA2906279A1 (en) | 2013-03-15 | 2014-09-18 | Pci Biotech As | A method of generating antigen presenting cells using photochemical internalisation |
GB2517707B (en) | 2013-08-28 | 2020-09-02 | Pci Biotech As | A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen |
JP6684215B2 (ja) | 2013-08-28 | 2020-04-22 | ピーシーアイ バイオテック エイエス | 予防接種用化合物および免疫化用化合物、ならびに予防接種方法および免疫化方法 |
AU2014390262B2 (en) | 2014-04-11 | 2020-11-26 | Pci Biotech As | Method of treating melanoma |
NZ729408A (en) | 2014-08-28 | 2021-12-24 | Pci Biotech As | A method of photochemical internalization (pci) utilizing a antigenic molecule, a photosensitizing agent, and a cytokine |
GB201503776D0 (en) | 2015-03-05 | 2015-04-22 | Pci Biotech As | Compound and method |
WO2016201136A1 (en) | 2015-06-10 | 2016-12-15 | Ekos Corporation | Ultrasound catheter |
WO2018069536A1 (en) | 2016-10-14 | 2018-04-19 | Pci Biotech As | Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine |
GB201718631D0 (en) * | 2017-11-10 | 2017-12-27 | Pci Biotech As | Method |
EP3823668A1 (en) | 2018-07-16 | 2021-05-26 | DCPrime B.V. | A combination product for use in tumor vaccination |
CA3133410A1 (en) | 2019-04-25 | 2020-10-29 | Dcprime B.V. | Methods of tumor vaccination |
CN110711249B (zh) * | 2019-09-19 | 2020-10-27 | 北京化工大学 | 一种溶酶体膜包覆纳米颗粒的制备方法 |
AU2021244937A1 (en) | 2020-03-27 | 2022-11-03 | Mendus B.V. | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
EP4127139A1 (en) | 2020-03-27 | 2023-02-08 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
CN114163508A (zh) * | 2020-09-11 | 2022-03-11 | 王月志 | 能破坏细胞的氨基酸序列及相关核苷酸序列和相关的应用 |
US20220168407A1 (en) | 2020-11-05 | 2022-06-02 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
GB202101726D0 (en) | 2021-02-08 | 2021-03-24 | Pci Biotech As | Method |
AU2022235341A1 (en) | 2021-03-12 | 2023-09-21 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
GB202115451D0 (en) | 2021-10-27 | 2021-12-08 | Pci Biotech As | Method |
WO2024068795A1 (en) | 2022-09-27 | 2024-04-04 | Pci Biotech As | Method for releasing viral vectors |
GB202404168D0 (en) | 2024-03-22 | 2024-05-08 | Pci Biotech As | Method |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU563827B2 (en) | 1982-07-01 | 1987-07-23 | Millipore Corp. | Filtration apparatus |
US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
US4704255A (en) | 1983-07-15 | 1987-11-03 | Pandex Laboratories, Inc. | Assay cartridge |
US5066274A (en) * | 1985-04-30 | 1991-11-19 | Nippon Petrochemicals Company, Ltd. | Tetrapyrrole therapeutic agents |
US5076950A (en) | 1985-12-20 | 1991-12-31 | Syntex (U.S.A.) Inc. | Magnetic composition for particle separation |
US4895706A (en) | 1986-10-28 | 1990-01-23 | Costar Corporation | Multi-well filter strip and composite assemblies |
US5095030A (en) * | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
HU204856B (en) | 1987-08-12 | 1992-02-28 | Orszagos Mueszaki Fejlesztesi | Process for releasing cell mixtures and tissues from undesired populations and for producing monoclonal antibody - hematoporphyrin conjugates |
NO891491D0 (no) * | 1987-08-12 | 1989-04-11 | Peter Nemeth | Prosedyre for befrielse av celleblandinger og vev for uoenskede populasjoner. |
GB8721108D0 (en) * | 1987-09-08 | 1987-10-14 | Salford University Of | Liposomes |
US5284647A (en) * | 1988-03-18 | 1994-02-08 | Schering Aktiengesellschaft | Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them |
US5256532A (en) | 1988-05-02 | 1993-10-26 | Zynaxis Technologies, Inc. | Methods, reagents and test kits for determination of subpopulations of biological entities |
US4925736A (en) * | 1988-07-06 | 1990-05-15 | Long Island Jewish Medical Center | Topical hematoporphyrin |
GB8905001D0 (en) | 1989-03-04 | 1989-04-19 | Univ Leicester | Screening for natural products of microbial metabolism |
US5567687A (en) * | 1989-03-06 | 1996-10-22 | University Of Texas | Texaphyrins and uses thereof |
US4935498A (en) * | 1989-03-06 | 1990-06-19 | Board Of Regents, The University Of Texas System | Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5059619A (en) * | 1989-06-14 | 1991-10-22 | Quadra Logic Technologies, Inc. | Stable freeze-dried polyhematoporphyrin ether/ester |
DE3919873A1 (de) | 1989-06-19 | 1990-12-20 | Behringwerke Ag | Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung |
GB8916859D0 (en) | 1989-07-24 | 1989-09-06 | Dynal As | Hapten linking |
GB8929297D0 (en) | 1989-12-29 | 1990-02-28 | Dynal As | Method of separation |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
US5491068A (en) | 1991-02-14 | 1996-02-13 | Vicam, L.P. | Assay method for detecting the presence of bacteria |
US5179120A (en) * | 1991-06-28 | 1993-01-12 | Cytopharm, Inc. | Porphycene compounds for photodynamic therapy |
PL165249B1 (pl) * | 1991-10-29 | 1994-11-30 | Wojskowa Akad Tech | Sposób otrzymywania soli kompleksowych hematoporfiryny i jej pochodnych PL PL PL PL PL PL PL |
US5376546A (en) * | 1991-11-04 | 1994-12-27 | Xoma Corporation | Analogs of ribosome-inactivating proteins |
US5258453A (en) * | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
CA2132094A1 (en) * | 1992-03-16 | 1993-09-30 | C. Frank Bennett | Oligonucleotide modulation of protein kinase c |
WO1993019199A1 (en) | 1992-03-20 | 1993-09-30 | Celsis Limited | Method and apparatus for the analysis of biological material |
CA2118513A1 (en) * | 1992-04-24 | 1993-11-11 | David A. Zarling | In vivo homologous sequence targeting in eukaryotic cells |
WO1994007138A1 (en) | 1992-09-14 | 1994-03-31 | Fodstad Oystein | Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations |
IL107480A0 (en) * | 1992-11-03 | 1994-02-27 | Gene Shears Pty Ltd | Tnf-x ribozymes and degradation resistant mrna derivatives linked to tnf-x ribozymes |
FR2700010B1 (fr) | 1992-12-24 | 1995-03-17 | Rocher Yves Biolog Vegetale | Méthode et dispositif pour tester la réactivité de cellules à l'égard de produits. |
US5374531A (en) | 1993-03-22 | 1994-12-20 | Zynaxis, Inc. | Immunoassay for determination of cells |
US5861310A (en) * | 1993-11-03 | 1999-01-19 | Dana-Farber Cancer Institute | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
US5491084A (en) * | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
US6015897A (en) * | 1993-12-07 | 2000-01-18 | Neorx Corporation | Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota |
US5514340A (en) | 1994-01-24 | 1996-05-07 | Magnetix Biotechnology, Inc. | Device for separating magnetically labelled cells |
NO180658C (no) | 1994-03-10 | 1997-05-21 | Oeystein Fodstad | Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner |
NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
US5872007A (en) * | 1995-02-17 | 1999-02-16 | Hybridon, Inc. | CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer |
-
1994
- 1994-09-08 NO NO943327A patent/NO180167C/no not_active IP Right Cessation
-
1995
- 1995-09-04 EP EP95932244A patent/EP0783323B1/en not_active Expired - Lifetime
- 1995-09-04 US US08/793,794 patent/US5876989A/en not_active Expired - Lifetime
- 1995-09-04 NZ NZ293008A patent/NZ293008A/en not_active IP Right Cessation
- 1995-09-04 DE DE69524238T patent/DE69524238T2/de not_active Expired - Lifetime
- 1995-09-04 WO PCT/NO1995/000149 patent/WO1996007432A1/en not_active Application Discontinuation
- 1995-09-04 AU AU35347/95A patent/AU700797B2/en not_active Expired
- 1995-09-04 CZ CZ97658A patent/CZ65897A3/cs unknown
- 1995-09-04 PT PT95932244T patent/PT783323E/pt unknown
- 1995-09-04 CN CNB951960652A patent/CN1222309C/zh not_active Expired - Lifetime
- 1995-09-04 ES ES95932244T patent/ES2163527T3/es not_active Expired - Lifetime
- 1995-09-04 JP JP50940496A patent/JP4148328B2/ja not_active Expired - Fee Related
- 1995-09-04 NZ NZ509519A patent/NZ509519A/en not_active IP Right Cessation
- 1995-09-04 AT AT95932244T patent/ATE209507T1/de active
- 1995-09-04 HU HU9800153A patent/HU222984B1/hu active IP Right Grant
- 1995-09-04 CA CA2199290A patent/CA2199290C/en not_active Expired - Lifetime
- 1995-09-04 BR BRPI9508825A patent/BRPI9508825B8/pt not_active IP Right Cessation
- 1995-09-04 MX MX9701676A patent/MX9701676A/es unknown
- 1995-09-14 KR KR1019970701520A patent/KR100395615B1/ko active IP Right Grant
- 1995-09-14 KR KR10-2003-7005142A patent/KR100529967B1/ko not_active IP Right Cessation
-
1997
- 1997-03-07 FI FI970983A patent/FI121328B/fi not_active IP Right Cessation
-
1998
- 1998-04-24 HK HK98103468A patent/HK1004110A1/xx not_active IP Right Cessation
- 1998-09-01 US US09/144,750 patent/US6680301B2/en not_active Expired - Fee Related
-
2002
- 2002-11-01 US US10/286,632 patent/US20030134813A1/en not_active Abandoned
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541072A (ja) * | 1999-03-15 | 2002-12-03 | フォトキュア エイエスエイ | 方 法 |
JP4593857B2 (ja) * | 1999-09-09 | 2010-12-08 | 株式会社東京大学Tlo | 膜の穿孔方法および装置 |
JP2004520020A (ja) * | 2000-11-29 | 2004-07-08 | ピーシーアイ バイオテック エイエス | ウィルス媒介の細胞質中への分子送達のための光化学的内在化 |
JP2004520021A (ja) * | 2000-11-29 | 2004-07-08 | ピーシーアイ バイオテック エイエス | 細胞質中への分子送達のための光化学的内在化 |
JP2005507383A (ja) * | 2001-08-30 | 2005-03-17 | ピーシーアイ バイオテック エイエス | 化合物 |
JP2021512063A (ja) * | 2018-01-24 | 2021-05-13 | ピーシーアイ バイオテック エイエス | 方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4148328B2 (ja) | 細胞サイトゾルへの化合物の移入 | |
Patrice | Photodynamic therapy | |
Berg et al. | Porphyrin‐related photosensitizers for cancer imaging and therapeutic applications | |
Detty et al. | Current clinical and preclinical photosensitizers for use in photodynamic therapy | |
US8096419B2 (en) | Compound | |
Sobolev et al. | Targeted intracellular delivery of photosensitizers | |
Oseroff et al. | Strategies for selective cancer photochemotherapy: antibody‐targeted and selective carcinoma cell photolysis | |
Kudinova et al. | Photodynamic therapy of cancer: Search for ideal photosensitizer | |
KR20010110664A (ko) | 광화학적 내부이행을 통해 항원 제시 세포의 표면상에항원을 발현시키는 방법 | |
Kostron et al. | Photodynamic therapy | |
US20010056065A1 (en) | Photosensitizers with ligand targeting properties for tumor therapy | |
CZ9727U1 (cs) | Prostředek pro modifikaci buněčných zejména nádorových procesů | |
EP1309330B1 (en) | Photosensitizers with ligand targeting properties for tumor therapy | |
AU2002313562C1 (en) | Compound | |
Wang | Studies of photochemical internalisation: mechanisms and strategies in cancer therapeutics | |
Woodhams et al. | Julie Tzu-Wen Wang | |
AU2002313562A1 (en) | Compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060627 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060901 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070710 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071023 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20071023 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080520 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080618 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110704 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110704 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120704 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120704 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130704 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |